ONCODNA
14.2.2020 11:02:06 CET | Business Wire | Press release
OncoDNA (“OncoDNA or “the Company”), the healthcare technology company making precision medicine a reality, today announced that it has completed a €19 million ($20 million) Series B equity financing. The new funding will support rapid international growth, accelerate software development and hiring initiatives.
The round was led by Vesalius Biocapital III and Swisscanto Invest by Zürcher Kantonalbank with the significant support of SFPI-FPIM. Historical shareholders together with CPH Bank, Inventures, Sambrinvest, Sofinim (Ackermans & Van Haaren) and SRIW have also participated. This represents another landmark achievement after the €8 million Series A fundraising closed in September 2016.
OncoDNA is now maximizing the fast and proper rollout of its oncology clinical decision support software OncoKDM® with the objective of becoming the European leader in oncogenomic data interpretation and reporting to further support molecular laboratories, healthcare professionals and the pharma industry in their daily research and clinical practice.
Jean-Pol Detiffe, Founder & Chief Executive Officer at OncoDNA : “We are delighted to have successfully raised sufficient new capital from such quality investors who will enable us to grow and increase our support to oncologists and cancer patients with our data driven solutions. OncoDNA is already positioned as the European champion for cancer precision medicine as we built a worldwide network of more than several thousand oncologists. Our next move is to connect molecular laboratories to our advanced data interpretation tools, which we pride ourselves on now being possible thanks to the support of our new investors.”
Guy Geldhof, Partner at Vesalius Biocapital III S.C.A. SICAR said: “We are excited about co-leading the Series B investment in OncoDNA. It is thrilling to work with a team that has both world class experience in genomic molecular profiling and a strong desire to serve patients by offering best-in-class support to oncology professionals. We are confident OncoDNA will accelerate the development and commercialization of its valuable new solutions, especially through closer collaborations with the biopharma industry, with the final objective of contributing to better healthcare .”
Robert Schier, Partner at Swisscanto (CH) Private Equity Switzerland Growth I KmGK added: “OncoDNA has grown significantly over the past years and are continuing to add the necessary clinical expertise and know-how to act upon its mission. Its disruptive vision and highly integrated market approach make it to be the perfect candidate to rapidly become the European leader in oncology big data. We are delighted to partner with OncoDNA as we firmly believe the company contributes to both a more sustainable healthcare system and improved patient health outcomes.”
“Considering our important investment in OncoDNA, alongside players like Vesalius Biocapital III and Swisscanto, we are convinced that the company has all the necessary means at a key moment of its development to successfully carry out appropriate projects to assist and support oncologists in prescribing the most optimal therapeutic treatments to patients. We are happy to count on the support of our colleagues from SRIW and Sambrinvest as historical stakeholders” concluded François Fontaine, at SFPI-FPIM.
OncoDNA
OncoDNA is a private, oncology-focused healthcare technology company that combines advanced, comprehensive testing of all clinically relevant cancer biomarkers (DNA, RNA and protein profiles) from both solid and liquid biopsies with a proprietary cancer treatment knowledge database. This one-stop-shop analysis and interpretation service gives oncologists actionable results to enable the selection of treatments tailored to the individual patient’s cancer profile. For laboratories worldwide with NGS facilities who would like to reach the same level of expertise, we provide them with state-of-the-art interpretation software to improve their oncology-oriented analyses routine work. The software OncoKDM is a web-based tool that processes oncology raw NGS data to turn data into clinical insight such as treatment options or clinical trials. OncoDNA also works in collaboration with the biopharma industry to develop and deliver the treatments of tomorrow by assisting with design, enrolment and assessment of clinical trials as well as increasing access to approved precision medicines. The company is based in Gosselies, Belgium, employs 50 employees in 4 countries, works with an international network of 35 distributors covering approx. 50 countries and is collaborating with a sub-contracted laboratory of 300 collaborators.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200214005149/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Factbird Adds Quality & Compliance and Reports to its Manufacturing Intelligence Platform20.5.2026 08:00:00 CEST | Press release
Two new capabilities give multi-site manufacturers standardized workflows, traceable records, and automated reporting across every plant. Today, Factbird is announcing two major additions to its manufacturing intelligence platform: Quality & Compliance and Factbird Reports. Both address a problem that compounds as manufacturers grow. More sites mean more variation in how work gets done. More regulation means more documentation pressure on frontline teams. And more data, when fragmented across systems, often slows decisions rather than speeding them up. Solving this has traditionally meant large IT projects and months of deployment. “Enterprise manufacturers shouldn’t have to choose between capability and simplicity,” said Mogens Arne Hansen, Chief Technology and Product Officerat Factbird. “With Quality & Compliance and Reports, you can have standardized, audit-ready operations and automated performance reporting across every site, deployed in days, used by the people on the floor.” Qu
The LYCRA Company to Successfully Complete Comprehensive Financial Restructuring20.5.2026 04:23:00 CEST | Press release
Company positioned for long-term growth, operational excellence, and continued customer-focused innovationWill emerge from financial restructuring with enhanced financial flexibility and significantly less debtNew ownership and Board of Directors committed to executing on vision to take the business to the next levelBruce Rubin appointed Executive Chairman and Dean Williams appointed Interim Chief Executive Officer The LYCRA Company, LLC (“the Company”), a global leader in developing fiber and technology solutions for the apparel and personal care industries, will successfully complete its comprehensive financial restructuring process and emerge from Chapter 11 protection on May 20, 2026. The LYCRA Company has established a durable capital structure that will enable the Company’s pursuit of its growth strategy through investment in innovation, customer partnerships, and global operations. The Company will emerge from its comprehensive restructuring process with significantly enhanced f
Johns Manville Announces John Vasuta as New CEO19.5.2026 22:30:00 CEST | Press release
Johns Manville (JM), a global building and specialty products manufacturer and a Berkshire Hathaway company, announced today that Bob Wamboldt will retire and John Vasuta will assume the role of President and Chief Executive Officer, effective August 1, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260519630814/en/ John Vasuta will become JM's CEO and President on August 1, 2026. Vasuta joined Johns Manville in 2019 as President of the company’s Engineered Products business. He also serves on the Board of Directors for EJ, a global leader and private manufacturer of infrastructure access products for water, sewer, utilities, drainage and telecommunications. “It’s an extraordinary privilege to step into the role of CEO,” Vasuta said. “I’m deeply honored to continue serving our customers and supporting the employees whose dedication makes our success possible.” Before joining JM, John held leadership roles at Bridgeston
Mereo Insurance Announces Move into Excess Casualty Insurance19.5.2026 22:12:00 CEST | Press release
Mereo expands into Excess Casualty Insurance by acquiring renewal rights to Everen Specialty Ltd.’s Excess Casualty Energy portfolio. Mereo Insurance Limited (“Mereo”) today announced a renewal rights transaction with Everen Specialty Ltd. (“ESL”), a member of the Everen Group, for ESL’s Excess Casualty Energy portfolio. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260519154915/en/ David Croom-Johnson, President & Chief Executive Officer of Mereo Insurance Limited Under the transaction, Mereo will become the insurance carrier on a go-forward basis for both new and renewed business effective June 1, 2026. ESL’s underwriting team and underwriting systems supporting the Excess Casualty Energy portfolio will also transition to Mereo, led by former ESL Chief Underwriting Officer, Carla Greaves. Under the terms of the agreement, Mereo will provide ESL insureds with continuity of coverage, access to AM Best “A- rated” paper, and
Grid Dynamics Launches AI-Native Modernization on Azure, Targeting Larger Enterprise Deals19.5.2026 22:05:00 CEST | Press release
Key Takeaways: New offerings target modernization of large enterprises running mission-critical, high-transaction-volume legacy environments. As a Microsoft Azure specialized partner with five advanced specializations, including Infra & Database Migration, Grid Dynamics’ clients will receive free deployment support through the Azure Accelerate program. Built on the GAIN (Grid Dynamics AI-Native) Platform for SDLC, which has delivered 30%+ productivity gains in our benchmarks. Grid Dynamics extends its AI delivery model to Azure, drawing on extensive expertise in application migration for Fortune 1000 companies. In the first quarter of 2026, AI represented 29% of the company’s revenue. This was up from 25% in 2025 and was driven by deployments across industry verticals, including Technology, Financial Services, CPG, and Manufacturing. Grid Dynamics Holdings, Inc. (Nasdaq: GDYN) (“Grid Dynamics”), a premier AI transformation partner for the Fortune 1000, today announced an AI-native mode
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom